Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Clinical Trials
Thu, 29/06/2017 - 07:30
Wed, 14/06/2017 - 07:30
Domainex Ltd. expands its partnership with Imperial College London, to discover novel therapies that reduce heart muscle damage during heart attacks.
Mon, 15/05/2017 - 10:00
London, UK, 15th May 2017 / Sciad Newswire / Orthonika Limited, a spin-out from Imperial College London, is pleased to ann
Mon, 24/04/2017 - 07:30
Phase 2a RSV Challenge Study Planned for Q3 2017
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4